Evidence map›Paper›PMID 30267565›Full record

ArticleBiotechnology and bioengineering2018

Process development for the continuous production of heterologous proteins by the industrial yeast, Komagataella phaffii.

Ayca Cankorur-Cetinkaya, Nathalie Narraidoo, Ceyda Kasavi, Nigel K H Slater, David B Archer, Stephen G Oliver

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Recombinant fibrous protein biomaterials meet skin tissue engineering.Frontiers in bioengineering and biotechnology · 2024
    Review
  6. Article
  7. Article
  8. Development of synthetic biology tools to engineerSynthetic and systems biotechnology · 2021
    Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Ayca Cankorur-CetinkayaDepartment of Biochemistry, Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-4431-7259
Nathalie NarraidooSchool of Life Sciences, University of Nottingham, University Park, Nottingham, United Kingdom.
Ceyda KasaviDepartment of Biochemistry, Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom.
Nigel K H SlaterDepartment of Chemical Engineering & Biotechnology, University of Cambridge, Cambridge University West Site, Cambridge, United Kingdom.
David B ArcherSchool of Life Sciences, University of Nottingham, University Park, Nottingham, United Kingdom.
Stephen G OliverDepartment of Biochemistry, Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-3410-6439
University of Cambridge · GBUniversity of Nottingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/F00446X/1Biotechnology and Biological Sciences Research Council BB/K011138/1
6 · The paper itself

Abstract

The current trend in industrial biotechnology is to move from batch or fed-batch fermentations to continuous operations. The success of this transition will require the development of genetically stable production strains, the use of strong constitutive promoters, and the development of new medium formulations that allow an appropriate balance between cell growth and product formation. We identified genes that showed high expression in Komagataella phaffii during different steady-state conditions and explored the utility of promoters of these genes (Chr1-4_0586 and FragB_0052) in optimizing the expression of two different r-proteins, human lysozyme (HuLy), and the anti-idiotypic antibody fragment, Fab-3H6, in comparison with the widely used glyceraldehyde-3-phosphate dehydrogenase promoter. Our results showed that the promoter strength was highly dependent on the cultivation conditions and thus constructs should be tested under a range of conditions to determine both the best performing clone and the ideal promoter for the expression of the protein of interest. An important benefit of continuous production is that it facilitates the use of the genome-scale metabolic models in the design of strains and cultivation media. In silico flux distributions showed that production of either protein increased the flux through aromatic amino acid biosynthesis. Tyrosine supplementation increased the productivity for both proteins, whereas tryptophan addition did not cause any significant change and, phenylalanine addition increased the expression of HuLy but decreased that of Fab-3H6. These results showed that a genome-scale metabolic model can be used to assess the metabolic burden imposed by the synthesis of a specific r-protein and then this information can be used to tailor a cultivation medium to increase production.

Indexed as

BioreactorsHumansImmunoglobulin FragmentsMuramidasePichiaRecombinant ProteinsSaccharomycetalesImmunoglobulin FragmentsMuramidaseRecombinant Proteinsantibodycontinuous bioprocessinghuman lysozyme (HuLy)Komagataella phaffii ( K. phaffi)Pichia pastoris ( P. pastoris)process optimization

Identifiers

PMID30267565
PMCPMC6283250
OpenAlexW2892722405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.